|
|
| Potamkin Prize Awarded to Elan Alzheimer's Scientist |
- Dr. Dale Schenk to Donate Prize Money to Post-Doctoral Program -
DUBLIN, Ireland, May 8 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN)
("Elan") today announced that Dale Schenk, Ph.D., senior vice president of
discovery research, will be the first-ever corporate recipient of the American
Academy of Neurology's ("AAN") prestigious Potamkin Prize. Dr. Schenk will
receive the award for his contributions to Alzheimer's disease research,
particularly the discovery of a potential immunotherapeutic being studied for
the treatment of Alzheimer's disease. Dr. Schenk will receive the award
today, at the AAN's annual meeting in Philadelphia. He intends to donate the
$100,000 cash award, which accompanies the Potamkin Prize, toward the
establishment of a post-doctoral program in Alzheimer's and Parkinson's
disease.
The Potamkin Prize was first awarded in 1988 to recognize and promote
excellence in neuroscientific research. It places a special focus on efforts
to find the cause of Alzheimer's disease, Pick's, and related diseases, and to
develop effective therapies for them.
Commenting on Dr. Schenk's achievement, Donal J. Geaney, Elan's chairman
and chief executive officer, said, "We are delighted that the AAN has selected
Dale as the recipient of this year's Potamkin Prize, acknowledging his
leadership role in the research and discovery of immunotherapeutic approaches
to the treatment of Alzheimer's disease. Elan is very proud of Dale, and we
are delighted that his years of work are being recognized with such a
prestigious honor. Dale's decision to fund a post-doctoral program with the
award money is a measure of his commitment to Alzheimer's and Parkinson's
disease research -- a commitment shared by everyone at Elan."
Elan is a leading worldwide fully integrated pharmaceutical company
headquartered in Ireland, with its principal research, development,
manufacturing and marketing facilities located in Ireland, the United States
and Israel. Elan is focused on the, discovery, development and marketing of
therapeutic products and services in neurology, pain management, oncology,
infectious disease and dermatology and on the development and
commercialization of products using its extensive range of proprietary drug
delivery technologies. Elan shares trade on the New York, London and Dublin
Stock Exchanges.
MAKE YOUR OPINION COUNT -- Click Here
SOURCE Elan Corporation, plc
back to topRelated links:
CONTACT:
Investors - U.S.: Jack Howarth, 212-407-5740
or 800-252-3526, Europe: Emer Reynolds, +353-1-709-4000 or
800-283-52600; Media - Max Gershenoff, 212-407-5740 or
800-252-3526, all for Elan Corporation, plc
